SCHEMBL5141399

SCHEMBL5141399

O=C(Nc1cccc(C(=O)O)c1)/C(=C/c1ccc(C(F)(F)F)nc1)C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.47
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
HTT P42858 4/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KCNK3 O14649 2/20 0.46
MAPT P10636 2/20 0.46
MRGPRX4 Q96LA9 1/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
TSHR P16473 1/20 0.45
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
ERBB2 P04626 1/20 0.44
KCNK9 Q9NPC2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5141400 1.00 AURKA (0.47) AURKAAKR1C3AKR1C2HTTRAB9A
SCHEMBL5142373 0.93 ERBB2 (0.49) HTTRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5145698 0.86 TSHR (0.53) MEN1KMT2ATSHR
SCHEMBL5145694 0.86 TSHR (0.53) MEN1KMT2ATSHR
SCHEMBL5144564 0.84 SMARCA2 (0.48) HTTMAPTMEN1KMT2ATSHR
SCHEMBL5144568 0.84 SMARCA2 (0.48) HTTMAPTMEN1KMT2ATSHR
SCHEMBL5144544 0.82 BRAF (0.49) RAB9ANPC1POLBMAPTMEN1
SCHEMBL5144541 0.82 BRAF (0.49) RAB9ANPC1POLBMAPTMEN1
SCHEMBL5145824 0.81 GAA (0.47) HTTRAB9APOLBSMN1; SMN2MAPT
SCHEMBL5142335 0.81 AKR1C3 (0.47) AURKAAKR1C3AKR1C2HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US claimed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO claimed
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US disclosed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CASP14, CASP2, CASP3 AURKA 661/4885AKR1C3 1032/4885AKR1C2 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.